Reviewing Athira Pharma (NASDAQ:LONA) and Liminatus Pharma (NASDAQ:LIMN)

Athira Pharma (NASDAQ:LONA) and Liminatus Pharma (NASDAQ:LIMN) are both small-cap manufacturing companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Athira Pharma and Liminatus Pharma, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1	1	2	0	2.25
Liminatus Pharma	1	0	0	0	1.00

Athira Pharma presently has a consensus target price of $10.00, indicating a potential upside of 62.07%. Given Athira Pharma’s stronger consensus rating and higher probable upside, research analysts plainly believe Athira Pharma is more favorable than Liminatus Pharma.

Profitability

This table compares Athira Pharma and Liminatus Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-107.06%	-89.89%
Liminatus Pharma	N/A	N/A	N/A

Valuation and Earnings

This table compares Athira Pharma and Liminatus Pharma”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$96.94 million	($9.68)	-0.64
Liminatus Pharma	N/A	N/A	N/A	($0.12)	-1.95

Liminatus Pharma is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

57.1% of Athira Pharma shares are held by institutional investors. 25.1% of Athira Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Athira Pharma beats Liminatus Pharma on 6 of the 9 factors compared between the two stocks.

About Athira Pharma

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company’s lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer’s disease, as well as is in Phase 2 clinical trials to treat Parkinson’s disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.

About Liminatus Pharma

Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.